Farampator (CX 691, ORG 24448 or (1-(benzofurazan-5-ylcarbonyl) piperidine)) is a positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors. Farampator exerts antipsychotic and cognitive enhancing properties.

Formetorex was studied as an anorexic agent that has never been marketed. Information about the current use of this compound is not available.

Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A). It exerts an inhibitory effect on noradrenaline and 5-hydroxytryptamine reuptakes. It has no effect on the dopaminergic and cholinergic systems. It has only a low potential for amplifying tyramine and noradrenaline pressor effect, which makes one expect that it will not be at the basis of a ‘cheese effect’. Pirlindole was approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treatment of depression. The drug's efficacy and safety have also been demonstrated in the treatment of fibromyalgia syndrome. Pirlindole has a favorable tolerability profile, with no deleterious effect on cardiovascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Pirlindole prevented qualitative alteration (transformation) in the catalytic activity of membrane-bound type A monoamine oxidases (MAO-A), pathogenetically important for the development of the audiogenic seizures.

Promolate is an Isobutyric acid derivative with potent antitussive activity. In preclinical studies, Promolate shows low toxicity in experimental animals and an antitussive action like that of codeine, but without the side effects of the latter. Promolate displayed a dose-dependent antitussive effect in conscious guinea pigs with coughing induced by NH3 aerosol. The activity of Promolate did not diminish when it was administered orally to guinea pigs for 20 days. Promolate also displayed a dose-dependent antitussive effect in Na barbital anesthetized cats with coughing induced by stimulation of the superior laryngeal nerve. High doses of Promolate administered to rats for 125 days did not provoke side effects.

Propipocaine (also known as falicaine) is an aromatic ketone derivative with potent local anaesthetic activity. The toxicity of Propipocaine has been worked out in mice. Given intravenously it is 4 times, and subcutaneously 10 times as toxic as procaine. Falicaine is suitable for surface anaesthesia in a concentration of 0.5 to 1 %. Higher concentrations cause irritation or even necrosis.

Propetamide (also known as FC 379) is a propionamide derivative patented by All-Union Scientific Research Chemical-Pharmaceutical Institute as an analgesic compound. In mice, Propetamide produced both a depression of spontaneous motility and relaxation of muscular tone. However, Propetamide was less active than meprobamate. Propetamide at 400 mg/kg reduced muscular relaxation in 70% of the animals, while the same effect was obtained in 100% of the animals with meprobamate at 200 mg/kg.

Dametralast is an antihistamine agent. Bronchodilator action of dametralast was demonstrated on the isolated trachea of guinea pigs. Dametralast prevents bronchospasm in anesthetized guinea-pigs, protects mice from anaphylactic shock induced by injection of bovine albumin, and has a protective effect in passive cutaneous anaphylaxis test in rats. Investigations into the mechanism of action have shown that the drug was ineffective on the synthesis of cyclooxygenase products from arachidonic acid. Dametralast inhibited cAMP phosphodiesterase (PDE) but this inhibition does not seem to be involved in their anti-inflammatory activity. In clinical tests dametralast was well tolerated; functional respiratory exploration determinations provided the same bronchodilator effect found in animals. A favorable effect was noted in asthmatic subjects and in subjects suffering from respiratory insufficiency.

Uredofos is a broad-spectrum anthelmintic. Uredofos is highly effective against canine tapeworms, ascarids, and hookworms when given as a single dose of 50 mg/kg and against whipworm when given at dose level of 50 mg/kg/day for 2 days. In mice complete removal of Hymenolepis nana occurred at 25 mg/kg and Syphacia obvelata was completely eliminated at all levels.

Dazidamine is an anti-inflammatory agent, developed by the Italian company Aziende Chimiche Riunite Angelini Francesco CRAF SpA. Dazidamine is claimed to have an anti-inflammatory activity which is manifested both through the topical and the systemic route, as well as a local anesthetic activity and a disinfectant action which manifests after topical application.

Dazoquinast is an imidazoquinoxaline derivative with antiallergic properties, developed by the British company Roussel Laboratories Ltd. Dazoquinast inhibited the IgE-mediated passive cutaneous anaphylaxis in rats passively sensitized to ovalbumen after intravenous and oral administration with ED50s of 0.073 and 0.13 mg/kg respectively.